Will you give a trial of tirzepatide in patients with PsA and obesity who have a partial response to bDMARD rather than switching their immunosuppressive regimen?

I don't believe the data on the magnitude of the benefit of GLP-1 agonists in arthritis symptoms is sufficient to suggest that adding one of these agents would be preferable to changing DMARDs in a patient with inadequate response.

Yes, we will give a GLP-1RA in selected patients who have an inadequate response to initial bDMARD or tsDMARD therapy. The major barrier is insurance approval.